Drug Database
AS

astromicin sulfate (astromicin sulfate / Astromicin)

✓ Approved

Kyowa Kirin Co., Ltd. · therapeutic agent

What is astromicin sulfate?

astromicin sulfate is a therapeutic agent developed by Kyowa Kirin Co., Ltd.. It is approved for therapeutic indications via unknown.

Drug Profile

Brand Namesastromicin sulfate, Astromicin
CompanyKyowa Kirin Co., Ltd.
RouteUnknown
StatusApproved

Therapeutic Indications

astromicin sulfate is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsSalmonellosis✓ Approved

Related Research Articles

PubMedDrug development and industrial pharmacy2026-08-30

Development of Extended-Release Oral Dosage Forms of Salbutamol Sulfate Using the Hot-Melt Extrusion Manufacturing Technique.

Ramadan Banan B, Al-Zoubi Nizar N, Migdadi Eman E, AlSuwais Alia Kh AK et al.

To fabricate and characterize extrudable polymeric matrices using a combination of ethyl cellulose (EC) and two different grades of hydroxypropyl cellulose (HPC) that can provide sustained drug release of the model drug salbutamol sulfate. Implementation of the Hot-Melt Extrusion (HME) technique in the fabrication of polymeric combinations that will provide ready-to-use matrices for sustained release dosage forms. Two formulation groups were developed; each with six formulations. The first group contained EC: HPC 370,000 ratios ranging from 55.52:13.8% to 6.9:62.46%, respectively. The second group contained EC: HPC 80,000 ranging from 59.4:10% to 9.4:60%, respectively. The release profiles were determined via in vitro studies to assess the ability of matrices to prolong salbutamol release. Solid-state characterization was also performed on the raw material and representative extrudates formulations using differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD) and polarized light microscopy (PLM). The first group formulations exhibited prolonged drug release profiles that accelerated progressively as the level of HPC 370,000 increased. In contrast, the second group formulations exhibited a noticeably faster release, demonstrating that HPC 80,000 can effectively accelerate drug release through enhanced matrix erosion and water penetration. DSC and XRPD revealed that the model drug remained in its stable crystalline state even after thermal processing via HME. PLM further confirmed drug crystallinity within the extrudates. EC-HPC matrices successfully demonstrated the feasibility of using HME to prepare sustained-release matrices for salbutamol sulfate with the ability to tune drug release by varying polymer grade and ratio.

PubMediScience2026-08-30

Contrasting chemical characteristics and secondary formation of PM2.5 from mountain and urban sites in central China.

Ren Lihong L, Li Hong H, Chen Shuang S, Zhang Renjian R et al.

The vertical distribution of aerosol is critical to understand the effect of aerosol on climate. This work explored chemical characteristics of PM2.5 at three urban and one mountain sites in Shiyan located in central China. Annual PM2.5 mass concentrations at the mountain site were 70% of urban levels. The total of sulfate, nitrate, and ammonium (SNA) dominated PM2.5, showing higher proportion (49.3%) at mountain site. SNA shows the homogeneous vertical distribution in spring, summer, and autumn with coefficient of divergences below 0.2, whereas most of components were more abundant at urban sites in winter. Higher nitrogen oxidation ratio (0.27) and ratio of secondary organic carbon to organic carbon (0.65) indicated that the aerosol in mountainous atmosphere exhibited a greater degree of aging compared to that at urban sites. These findings enhance our understanding of the vertical distribution of PM2.5 composition and provide a scientific foundation for regional atmospheric pollution control.

PubMedPeerJ2026-08-30

Identification and validation of novel platelet-related genes in ulcerative colitis using bioinformatics and machine learning strategies.

Huang Jin J, Dai Ying Y, Lu Shuangshuang S, Li Xue X et al.

Ulcerative colitis (UC) is a chronic, relapsing inflammatory disorder of the colonic mucosa. Although colonoscopy remains the diagnostic cornerstone for UC, its invasive nature highlights the need for additional biomarkers. This study used differential expression analysis, weighted gene co-expression network analysis (WGCNA), and machine-learning algorithms to identify three key platelet-related genes (PRGs)-TRIM22, TIMP1, and RAC2-that are involved in UC development. Immune cell analysis and single-cell analyses indicated that the expression of these key genes was significantly correlated with macrophages, neutrophils, and mast cells. Moreover, these key PRGs were mainly involved in pathways related to UC, such as chemokine signaling and leukocyte transendothelial migration. The expression levels of the key PRGs were further validated in independent datasets, dextran sulfate sodium (DSS)-induced colitis tissues, and peripheral blood mononuclear cells (PBMC) samples from UC patients. Collectively, these findings support a platelet-related three-gene signature with potential diagnostic and biological relevance in UC.

PubMedBioactive materials2026-08-30

Reversing zinc dyshomeostasis and oxidative stress: A metallothionein 1-activating MXene/Zn2+ triple-action nanotherapeutic strategy for chronic non-bacterial prostatitis.

Liu Kailai K, Zhang Yuchen Y, Gao Yanyao Y, Zheng Yunhe Y et al.

Chronic non-bacterial prostatitis (CNP), a prevalent and debilitating urological disorder affecting 8.4% of men aged 15-60 years, presents significant clinical challenges due to the paucity of targeted therapies and poor patient adherence. To address this unmet medical need, we developed an innovative multifunctional nanoplatform (QM (Zn) NPs) by integrating Ti3C2 MXene with a quercetin-zinc coordination complex (Que-Zn) for precision CNP therapy. This system leverages chondroitin sulfate (Chs)-mediated CD44 targeting to achieve selective accumulation in inflamed prostate tissue, thereby enhancing Zn2+ bioavailability while enabling co-delivery of MXene and Que-Zn therapeutic payloads. Upon localization, QM (Zn) NPs orchestrate a coordinated therapeutic cascade: MXene scavenges reactive oxygen species (ROS) via electron-deficient sites, while Que-Zn drives M1-to-M2 macrophage repolarization and facilitates Zn2+ cellular uptake. The accumulated intracellular Zn2+ critically upregulates metallothionein 1 (Mt1), activating the IKK/NF-κB/IκB axis to resolve inflammation and oxidative damage. Transcriptomic analysis unequivocally identified Mt1 as the pivotal mediator of Zn2+-driven microenvironment reprogramming. Notably, QM (Zn) NPs not only significantly alleviated pelvic pain by mitigating neuronal oxidative stress but also exhibited excellent biocompatibility. This work pioneers a targeted nano-theranostic strategy that synergistically restores zinc homeostasis, quenches ROS, and reprograms immune responses, thereby establishing a transformative paradigm for CNP management.

PubMedMarine life science & technology2026-08-30

From discovery to mechanism: novel anti-ulcerative colitis meroterpenoids act through the PI3K/IκB-α/MAPK pathway.

Yang Jiafan J, Liang Chuxing C, Chang Binglin B, He Jingxin J et al.

Ulcerative colitis (UC) is a chronic inflammatory bowel disease for which treatment options remain limited and therapeutic outcomes are often unsatisfactory. In this study, an anti-inflammatory activity-guided investigation led to the isolation of 12 compounds, including 11 new meroterpenoids (1-11) and the known compound aspermeroterpene B (12). Bioaspertermeroterpene A (1) was identified as the first meroterpenoid featuring a novel 6/6/6/7 tetracyclic ring system. In anti-inflammatory assays, compounds 10-12 significantly inhibited lipopolysaccharide (LPS)-induced nitric oxide (NO) production in RAW 264.7 macrophages, with IC50 values of 21.0, 26.7, and 14.1 μmol/L, respectively, outperforming the positive control indomethacin (IC50 = 24.1 μmol/L). These compounds also downregulated the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Further mechanistic investigations revealed that compound 12 exerts its anti-inflammatory effects by modulating the PI3K/IκB-α/MAPK signaling pathway. In a dextran sulfate sodium (DSS)-induced murine colitis model, compound 12 demonstrated remarkable therapeutic efficacy by alleviating disease symptoms, restoring intestinal barrier integrity, and suppressing colonic inflammation by downregulating iNOS and tumor necrosis factor-α (TNF-α). Collectively, this study not only reveals a class of structurally novel meroterpenoids with potent anti-UC activity but also identifies compound 12 as a highly promising lead candidate for the treatment of inflammatory bowel disease. The online version contains supplementary material available at https://doi.org/10.1007/s42995-026-00371-8.

PubMedInternational journal of pharmaceutics: X2026-08-30

Water-triggered in-situ gelling phospholipid oil enema for enhanced budesonide delivery and mucosal healing in ulcerative colitis.

Ouyang Ting T, Chen Yumo Y, Jia Yiying Y, Li Jiarui J et al.

Budesonide (BUD) enema therapy for ulcerative colitis (UC) is limited by poor solubility, inadequate bio-adhesion, and rapid clearance due to intestinal peristalsis. To address the limitations of conventional budesonide enemas, we designed a water-triggered in situ phase-transition phospholipid formulation (termed PG oil). This system comprises soybean phosphatidylcholine (PC-98), glyceryl dioleate (GDO), propylene glycol, and anhydrous ethanol, and achieves markedly enhanced BUD solubilization (35 mg/mL), in contrast to its negligible aqueous solubility (0.021 mg/mL). Upon contact with colonic fluid, PG oil rapidly underwent sol-gel transition, forming a bio-adhesive lamellar liquid crystalline gel that serves as both a physical mucosal barrier and a sustained-release drug depot. In a dextran sulfate sodium (DSS)-induced colitis mouse model, rectal administration of BUD-PG oil (0.3 mg/kg) significantly outperformed free BUD suspension, as evidenced by restored body weight, reduced disease activity index, normalized colon length, and decreased spleen index. Immunohistochemistry revealed marked suppression of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β, MCP-1) in colonic tissue. Histological analysis demonstrated that BUD-PG promoted favorable mucosal repair characterized by reduced collagen deposition (Masson's trichrome: from 48.5% to 16.7%) while restoring gut barrier integrity through replenishment of goblet cells and upregulation of tight junction proteins (ZO-1, Occludin-1, Claudin-5, β-catenin). Collectively, this water-responsive in situ gelling phospholipid oil platform addresses critical limitations of conventional BUD enemas by combining sustained local drug delivery with physical mucosal protection, offering a promising therapeutic strategy for comprehensive mucosal healing in UC.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about astromicin sulfate